Exhibit 107
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
IDEAYA Biosciences, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price(1) |
Fee Rate |
Amount of Registration Fee(1) | |||||||||
| Newly Registered Securities | ||||||||||||||||
| Fees to Be Paid |
Equity | Common Stock, $0.0001 par value per share |
Rule 457(r) | 8,641,429(2) | $35.00 | $302,450,015 | 0.00014760 | $44,641.63 | ||||||||
| Fees to Be Paid |
Equity | Pre-funded warrants to purchase common stock |
Rule 457(r) | 285,715 | $35.00(3) | $—(3) | 0.00014760 | $— | ||||||||
| Fees Previously Paid |
N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||
| Carry Forward Securities | ||||||||||||||||
| Carry Forward Securities |
N/A | N/A | N/A | N/A | N/A | |||||||||||
| Total Offering Amounts | $302,450,015 | $44,641.63(1) | ||||||||||||||
| Total Fees Previously Paid | $— | |||||||||||||||
| Total Fee Offsets | $— | |||||||||||||||
| Net Fee Due | $44,641.63 | |||||||||||||||
| (1) | In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended (the “Securities Act”), the registrant initially deferred payment of all of the registration fees for the Registration Statement on Form S-3 (Registration No. 333-272936), filed on June 26, 2023. |
| (2) | Includes 1,127,142 shares of common stock that the underwriters have an option to purchase and 285,715 shares of common stock that are issuable upon the exercise of pre-funded warrants referenced below. |
| (3) | Represents the sum of the pre-funded warrants sales price of $34.9999 per pre-funded warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the pre-funded warrants. |